ClinicalTrials.gg
Status unknownNCT05466864Updated Jul 20, 2022

Screening of OSA in Hospitalized Stroke Patients Using BSP

An interventional study of Belun Sleep platform in Sleep-Disordered Breathing, Sleep Architecture and Stroke, Acute, sponsored by Taipei Medical University Shuang Ho Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Taipei Medical University Shuang Ho Hospital · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Obstructive sleep apnea (OSA) is prevalent in patients with stroke and has a negative effect on outcomes by predisposing them to recurrent stroke, increasing mortality, and so forth. Therefore, it is extremely important to identify OSA in patients with stroke.

Wearable devices can greatly reduce the manpower and material requirements of traditional laboratory-based polysomnography (PSG). With Photoplethysmography (PPG) technology and neural network algorithms, the Belun ring and the sleeping platform not only can detect blood oxygen, and heart rate but also can identify sleep stage and estimate the severity of sleep apnea.

In this study, inpatients with acute ischemic stroke in the hospital will proceed with three nights test for recording the parameters of the autonomic nervous system in the acute phase, evaluate whether sleep apnea and the feasibility of the Belun sleep platform.

It is important that early recognition of OSA and prompt treatment, which can potentially improve OSA-associated adverse outcomes, as well as understanding the degree of autonomic nervous function impairment for patients with acute ischemic stroke. After smoothing this process, it can help clinicians more accurately comprehend the condition, timing of admission, and discharge.

02

Conditions studied

  • Sleep-Disordered Breathing
  • Sleep Architecture
  • Stroke, Acute

Keywords

  • Obstructive Sleep Apnea
  • Central Sleep Apnea
  • Stroke
  • Sleep Position
03

In context

Sleep Apnea Syndromes

2,183 studies on the registry are indexed under Sleep Apnea Syndromes; 284 are open to participants now.

This study's planned enrollment of 120 is above the median of 53 across 1,400 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

Taipei Medical University Shuang Ho Hospital is the lead sponsor of 101 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients with confirmed acute ischemic stroke
  • Age 18-80
  • Able to consent

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation, LVEF \< 45%, pacemaker/defibrillator, left ventricular assist device (LVAD), or status post-cardiac transplantation, devastating strokes ( mRS >= 4).
  • Aphasia, severe bulbar palsy, unable to comprehend, consent, or answer questionnaires.
  • Unstable cardiopulmonary status.
  • Recent surgery including tracheotomy in 30 days.
  • On narcotics.
  • On O2, PAP device, ventilator, diaphragmatic pacing, or any form of nerve stimulator
  • unable to understand instructions or to accurately use BRP during the instruction session.
  • Patients with technically valid recording time under 4 hours will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    TMU Hospital

    Potential participants with suspected OSA will be identified from the schedule of the TMU sleep labs. Those subjects who satisfy the study conclusion and exclusion criteria will be approached and invited to participate in the study.

    Device: Belun Sleep platform

Interventions

  • DeviceBelun Sleep platform

    BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.

06

What researchers measure

Primary outcomes

  1. AHI, duration with SpO2 < 90%, and SpO2 nadir, as well as sleep stage parameters (total sleep time [TST], wake time, REM time, and NREM time)

    To specifically assess the accuracy of BSP bAHI in predicting OSA by comparing to the concurrent in-lab PSG-AHI and to determine the accuracy of BSP sleep stage parameters by comparing to the concurrent PSG. BSP bAHI, BSP time with SpO2 \< 90%, and BSP-SpO2 nadir will be extracted from BSP and compared to PSGAHI (4% hypopnea criteria), PSG time with SpO2 \< 90% (PSG-T90), PSG-SpO2 nadir extracted from the concurrent PSG. BSP sleep stage parameters (total sleep time \[TST\], wake time, REM time, and NREM time) will be extracted from BSP and compared to the same parameters of the concurrent PSG. Epoch-by-epoch comparison will be performed.

    Time frame: 1 year

Secondary outcomes

  1. Duration of BSP use and technically valid recording time

    Duration of BSP use and technically valid recording time will be extracted from BSP for assessment feasibility of BSP testing in hospitalized patients.

    Time frame: 1 year

  2. Score of STOP-Bang

    Stop-Bang cutoff of 3, 4, and 5 will be combined with PSG-cutoff of 5 events/h, 15 events/h, and 30 events/h and compared for accuracy of OSA prediction.

    Time frame: 1 year

  3. HRV parameters (including both frequency and time domain) ,the length of hospital stay, NIH Stroke Scale (NIHSS) score, and modified Rankin score (mRS)

    ANS parameters including HRV frequency domain parameters (low frequency \[LF\], high frequency \[HF\], and LF/HF ratio) as well as time domain parameters (standard deviation of normal to normal R-R intervals \[SDNN\] and root mean square of successive heartbeat interval difference \[RMSSD\]) will be extracted from BSP and test the correlations with the length of hospital stay, NIH Stroke Scale (NIHSS) score, and modified Rankin score (mRS) will be analyzed.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 235, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05466864
Responsible party
Wen-De Liu (Director of Sleep Center, Taipei Medical University Shuang Ho Hospital) — Principal investigator
First posted
Jul 20, 2022
Start date
May 4, 2022
Primary completion
May 3, 2023 (estimated)
Completion
May 3, 2024 (estimated)
Last update
Jul 20, 2022

Study contacts

Wen-Te Liu, MD. PhD
Contact
b7801077@tmu.edu.tw
+886-222490088 ext. 72431
Wen-Te Liu, MD. PhD
study director · Taipei Medical University Shuang Ho Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion